Roivant Sciences Ltd
ROIV19.870USD
+0.270+1.38%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
13.56BMarket Cap
LossP/E TTM
More Details of Roivant Sciences Ltd Company
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.
Roivant Sciences Ltd Info
Ticker SymbolROIV
Company nameRoivant Sciences Ltd
IPO dateDec 03, 2020
CEODr. Eric Venker, M.D.
Number of employees750
Security typeOrdinary Share
Fiscal year-endDec 03
Address7Th Floor, 50 Broadway
CityLONDON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited Kingdom
Postal codeSW1H 0DB
Phone4412955950
Websitehttp://roivant.com/
Ticker SymbolROIV
IPO dateDec 03, 2020
CEODr. Eric Venker, M.D.
Company Executives of Roivant Sciences Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.35M
--
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
187.68K
-2.33%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
99.80K
+1.24%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.14K
+0.69%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
+4.20%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
40.50K
+2.68%
Mr. Daniel Gold
Mr. Daniel Gold
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.35M
--
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
187.68K
-2.33%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
99.80K
+1.24%
Revenue Breakdown
FY2025Q1
By BusinessUSD
Name
Revenue
Proportion
VTAMA
55.13M
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
55.13M
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
VTAMA
55.13M
0.00%
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dexcel Pharma Technologies, Ltd.
15.06%
SB Investment Advisers (UK) Limited
8.78%
Fidelity Management & Research Company LLC
8.13%
Ramaswamy (Vivek)
7.16%
The Vanguard Group, Inc.
5.75%
Other
55.12%
Shareholders
Shareholders
Proportion
Dexcel Pharma Technologies, Ltd.
15.06%
SB Investment Advisers (UK) Limited
8.78%
Fidelity Management & Research Company LLC
8.13%
Ramaswamy (Vivek)
7.16%
The Vanguard Group, Inc.
5.75%
Other
55.12%
Shareholder Types
Shareholders
Proportion
Investment Advisor
26.27%
Investment Advisor/Hedge Fund
19.95%
Hedge Fund
15.83%
Corporation
15.06%
Private Equity
11.50%
Individual Investor
11.07%
Research Firm
2.05%
Pension Fund
0.50%
Venture Capital
0.45%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
685
526.71M
77.13%
-106.87M
2025Q2
673
776.63M
112.42%
-147.35M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
2023Q2
394
761.99M
100.91%
+10.72M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dexcel Pharma Technologies, Ltd.
102.85M
15.06%
--
--
Jul 01, 2025
SB Investment Advisers (UK) Limited
59.95M
8.78%
-1.90M
-3.07%
Jun 30, 2025
Fidelity Management & Research Company LLC
55.50M
8.13%
+3.83M
+7.41%
Jun 30, 2025
Ramaswamy (Vivek)
48.92M
7.16%
-1.78M
-3.50%
Sep 05, 2025
The Vanguard Group, Inc.
39.25M
5.75%
-1.44M
-3.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
35.53M
5.2%
-1.48M
-4.00%
Jun 30, 2025
Viking Global Investors LP
34.24M
5.01%
-11.78M
-25.59%
Jun 30, 2025
Morgan Stanley Investment Management Inc. (US)
33.37M
4.89%
+2.37M
+7.64%
Jun 30, 2025
QVT Financial LP
29.38M
4.3%
-36.41M
-55.34%
Jun 30, 2025
Rubric Capital Management LP
20.37M
2.98%
+2.60M
+14.65%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Invesco S&P MidCap 400 Pure Growth ETF
2.77%
Virtus LifeSci Biotech Products ETF
2.2%
SPDR S&P Biotech ETF
1.82%
WisdomTree US Value Fund
1.3%
Goldman Sachs Future Health Care Equity ETF
1.25%
ProShares Ultra Nasdaq Biotechnology
1.07%
WisdomTree BioRevolution Fund
1.06%
Invesco Nasdaq Biotechnology ETF
1.04%
Direxion Daily S&P Biotech Bull 3X Shares
1.04%
WisdomTree US MidCap Fund
0.96%
View more
Invesco S&P MidCap 400 Pure Growth ETF
Proportion2.77%
Virtus LifeSci Biotech Products ETF
Proportion2.2%
SPDR S&P Biotech ETF
Proportion1.82%
WisdomTree US Value Fund
Proportion1.3%
Goldman Sachs Future Health Care Equity ETF
Proportion1.25%
ProShares Ultra Nasdaq Biotechnology
Proportion1.07%
WisdomTree BioRevolution Fund
Proportion1.06%
Invesco Nasdaq Biotechnology ETF
Proportion1.04%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.04%
WisdomTree US MidCap Fund
Proportion0.96%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
